经导管肝动脉栓塞治疗肝癌的远期疗效观察

262例原发性肝癌行经导管肝动脉注射碘油抗癌药混悬剂栓塞化疗（LP－TAE）后随访4～5年，生存3年以上52例，其中27例生存4年以上，8例生存5年以上，3、4、5年累计生存率分别为21．04％，11．64％和4．03％（寿命表法）。与同期生存3年以内的210例对照比较，结果表明病程分期、肝功能、肿瘤大小与生长方式、肿瘤供血丰富程度、是否伴有门脉癌柱与A－V分流、是否加用明胶海绵栓塞、Lp－TAE后碘油沉积范围、治疗后肿瘤缩小程度、AFP是否降为正常、是否伴发肝内外转移是影响肝癌Lp－TAE远期疗效的重要因素。

Long-term Result of Transcatheter Hepatic Artery Embolization for Primary Hepatic Carcinoma

Two hundred and sixty-two patients with primary hepatic carcinoma treated with Lipiodol transcatheter hepatic artery embolization (Lp-TAE) were followed up for 4-5 years. Fifty-two of the patients survived for more than 3 years. Among them, 27 patients survived for more than 4 years and 8 patlents more than 5 years. The 3-, 4-, 5-year survival rates were 21. 04%, 11. 64% and 4. 03 % respectively. As compared with 210 cases who survived less than 3 years, it is demonstrated that clinical stage, impairment of liver function, tumor size, growing pattern, blood supply of tumor, presence of portal tumor thrombi and A-V shunt,use of gel form embolization,extent of Lipiodol deposition, shrinkage of the tumor,decline of AFP and presence of metastasis were the most important factors affecting the long-term effect of Lp-TAE in the treatment of primary hepatic carcinoma.